Bromocriptine-responsive supersellar germinoma with the expression of dopamine receptors: A case report

Clin Neurol Neurosurg. 2019 Jan:176:15-18. doi: 10.1016/j.clineuro.2018.11.006. Epub 2018 Nov 10.

Abstract

Background: Germinomas are sensitive to radiotherapy and chemotherapy. However, there has been no report involving in the potential therapeutic effect of dopamine agonists (DAs) such as bromocriptine on germinomas.

Case description: A 20-year-old female was presented with bitemporal visual disturbance and amenorrhea. Magnetic resonance imaging demonstrated a huge sellar tumor with upward extension and invasion of the parasellar region. The blood tests showed an exceedingly high level of prolactin. A sellar tumor with hyperprolactinemia was diagnosed, and bromocriptine was initially given. After three months, the tumor volume had been obviously decreased by 82%. However, the tumor re-grew after ten months and the endoscopic endonasal surgery was performed. Histopathological and immunohistochemical examination indicated the patient had a pure sellar germinoma. The tumor cells strongly expressed dopamine 2 receptor and dopamine 5 receptor, which located in the membrane and cytoplasm.

Conclusions: The transient but significant partial responsiveness of germinoma to bromocriptine treatment in this patient is a novel discovery, suggesting that DAs may be a potential therapeutic choice for tumors with the expression of dopamine 2/5 receptors.

Keywords: Bromocriptine; Dopamine receptor; Germinoma.

Publication types

  • Case Reports

MeSH terms

  • Brain Neoplasms / drug therapy*
  • Bromocriptine / therapeutic use*
  • Dopamine Agonists / therapeutic use*
  • Female
  • Germinoma / drug therapy*
  • Humans
  • Pituitary Neoplasms / drug therapy
  • Prolactin / blood
  • Receptors, Dopamine / drug effects*
  • Young Adult

Substances

  • Dopamine Agonists
  • Receptors, Dopamine
  • Bromocriptine
  • Prolactin